CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

Biocon Facility Completes Pre Approval U.S. FDA Inspection

  • Posted by: Biocon Biologics

NOTIFICATION TO STOCK EXCHANGE

Company Statement

Bengaluru, India, Mar 06, 2019

“This is to inform you that the U.S. FDA concluded a pre-approval inspection of Biocon’s insulin drug substance manufacturing facility triggered by a New Drug Application submitted by our insulin API customer.

The inspection at the Bengaluru facility took place between 25th Feb – 5th Mar, 2019, resulting in a Form 483 with six observations.

Biocon is confident of addressing these expeditiously and remains committed to global standards of Quality and Compliance”

– Company Spokesperson

Author: Biocon Biologics
Share